University Hospitals Coventry and Warwickshire NHS Trust
NICE recommends axunio’s Axhidrox cream for adults with severe hyperhydrosis
Excessive sweating affects 1-5% of the population and can have a substantial impact on quality of life
Number of women in England receiving HRT on the NHS more than doubles
A record two million women were prescribed hormone replacement therapy in 2025/26 compared to 0.8 million in 2020/21
Permission to pause: making treatment breaks part of the cancer care conversation
Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.
Key takeaways from ASCO® 2026
Following ASCO® 2026, Inizio's experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year's congress revealed for pharmaceutical organisations. Together, they...
Webcast | Smarter science, sharper strategy: Expert perspectives from ASCO® 2026
Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.
Pfizer and Innovent Biologics agree on deal worth up to $10.5bn
The companies plan to research and develop 12 new cancer treatments
Durbin PLC becomes Uniphar, bolstering medicine access amidst growing healthcare demands
Against the backdrop of widespread medicine shortages, Durbin PLC’s rebrand to Uniphar and integration into Uniphar | Global Sourcing represents a strategic move to address industry-wide challenges, expanding its sourcing...
One-carbon Therapeutics collaborates with Tempus in cancer treatment
The treatment is currently being evaluated in a phase 1/2 multicentre clinical study
Gilead to acquire Tubulis for up to $5bn
The acquisition builds on Gilead’s oncology pipeline, focused on addressing areas of high unmet need
Incyte Biosciences UK announces NICE approval for Opzelura for vitiligo
This is the first approved treatment option in the UK for patients with non-segmental vitiligo
Vibrant Therapeutics raises $61m in funding to advance intelligent therapeutics pipeline
The financing includes new investors Pfizer Ventures and Apricot Capital, bringing the total capital raised to $100m
AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer
Around one in five breast cancer cases are HER2-positive